scholarly journals Tanshinone IIA induces cell death via Beclin-1-dependent autophagy in oral squamous cell carcinoma SCC-9 cell line

2018 ◽  
Vol 7 (2) ◽  
pp. 397-407 ◽  
Author(s):  
Ye Qiu ◽  
Conghua Li ◽  
Qinhua Wang ◽  
Xingqi Zeng ◽  
Ping Ji
2020 ◽  
Vol 21 (17) ◽  
pp. 6076
Author(s):  
Taís Bacelar Sacramento de Araújo ◽  
Leonardo de Oliveira Siquara da Rocha ◽  
Manuela Torres Andion Vidal ◽  
Paulo Lucas Cerqueira Coelho ◽  
Mitermayer Galvão dos Reis ◽  
...  

Due to its importance in the pathogenesis of oral squamous cell carcinoma (OSCC), the Hedgehog (HH) pathway is considered a potential therapeutic target. We investigated the effects of GANT61, a GLI inhibitor, on HH gene expression, as well as on metastatic OSCC cell proliferation and death. Following culture in DMEM medium, cytotoxicity of GANT61 against different tumor and non-tumor cell types was assessed by alamarBlue assays. Cytotoxicity analysis revealed that the metastatic HSC3 cell line was the most sensitive (IC50: 36 µM) to the tested compound. The compound’s effects on the expression of HH pathways components were analyzed by qPCR and Western blot; cell viability was analyzed by trypan blue assay and flow cytometry were used to investigate cell cycle phase, morphology, and death patterns in HSC3 cells. A significant reduction in mRNA levels of the GLI1 transcription factor was found after 12 h of treatment withGANT61. Protein expression levels of other HH pathway components (PTCH1, SHH, and Gli1) and HSC3 cell viability also decreased after 24 h of treatment. Cell cycle analysis and death pattern evaluations revealed significantly increased nuclear fragmentation in sub-G1 phase, as well as cell death due to apoptosis. In conclusion, the significantly reduced GLI1 gene expression seen in response to the GLI inhibitor indicates diminished downstream activation in HH pathway components. GANT61 significantly reduced cell viability in the metastatic cell line of OSCC and promoted a significant increase in nuclear fragmentation and cell death by apoptosis.


2021 ◽  
Vol 11 (10) ◽  
pp. 4559
Author(s):  
Jinyoung Park ◽  
Yoon-Seo Jang ◽  
Jeong-Hae Choi ◽  
Miheon Ryu ◽  
Gyoo-Cheon Kim ◽  
...  

Combination therapies for the treatment of oral squamous cell carcinoma have been studied extensively and represent a synergistic approach with better outcomes than monotherapy. In this study, a novel combination therapy was investigated using gold nanoparticles (GNP) conjugated to programmed cell death protein ligand 1 (PD-L1) antibodies and nonthermal plasma (NTP). The present study describes the effectiveness of NTP using PD-L1 antibody conjugated to GNP in PD-L1 expressing SCC-25 cells, an oral squamous cell carcinoma line. Immunocytochemistry revealed higher levels of PD-L1 expression and an increase in the selective uptake of PD-L1 antibody + GNP on SCC-25 cells compared to HaCaT cells. In addition, cell viability analyses confirmed higher levels of cell death of SCC-25 cells after treatment with PD-L1 antibody, GNP, and NTP compared to HaCaT cells. Among the experimental groups, the highest cell death was observed upon treatment with PD-L1 antibody + GNP + NTP. Following the Western blot analysis and immunofluorescence staining, the expression of apoptosis-related proteins was found to increase after treatment with PD-L1 antibody + GNP + NTP among the other experimental groups. In conclusion, the treatment of SCC-25 cells with PD-L1 antibody + GNP + NTP significantly increased the number of dead cells compared to other experimental groups. The results of this in vitro study confirmed the therapeutic effects of PD-L1 antibody + GNP + NTP treatment on oral squamous cell carcinoma.


Oncotarget ◽  
2016 ◽  
Vol 7 (34) ◽  
pp. 55057-55068 ◽  
Author(s):  
Talita Antunes Guimarães ◽  
Lucyana Conceição Farias ◽  
Eliane Sobrinho Santos ◽  
Carlos Alberto de Carvalho Fraga ◽  
Lissur Azevedo Orsini ◽  
...  

2017 ◽  
Vol 69 (6) ◽  
pp. 911-919 ◽  
Author(s):  
Raheleh Jabini ◽  
Melika Ehtesham-Gharaee ◽  
Zohreh Dalirsani ◽  
Fatemeh Mosaffa ◽  
Zahra Delavarian ◽  
...  

2018 ◽  
Vol 19 (9) ◽  
pp. 2485 ◽  
Author(s):  
Stephanie Hehlgans ◽  
Patrick Booms ◽  
Ömer Güllülü ◽  
Robert Sader ◽  
Claus Rödel ◽  
...  

Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation sensitizing effects of vismodegib by analyzing viability, cell cycle distribution, cell death, DNA damage repair and clonogenic survival in three-dimensional cultures of a BCC and a head and neck squamous cell carcinoma (HNSCC) cell line. We found that vismodegib decreases expression of the Hedgehog target genes glioma-associated oncogene homologue (GLI1) and the inhibitor of apoptosis protein (IAP) Survivin in a cell line- and irradiation-dependent manner, most pronounced in squamous cell carcinoma (SCC) cells. Furthermore, vismodegib significantly reduced proliferation in both cell lines, while additional irradiation only slightly further impacted on viability. Analyses of cell cycle distribution and cell death induction indicated a G1 arrest in BCC and a G2 arrest in HNSCC cells and an increased fraction of cells in SubG1 phase following combined treatment. Moreover, a significant rise in the number of phosphorylated histone-2AX/p53-binding protein 1 (γH2AX/53BP1) foci in vismodegib- and radiation-treated cells was associated with a significant radiosensitization of both cell lines. In summary, these findings indicate that inhibition of the Hedgehog signaling pathway may increase cellular radiation response in BCC and HNSCC cells.


2019 ◽  
Vol 235 (2) ◽  
pp. 1663-1673 ◽  
Author(s):  
Purushoth Ethiraj ◽  
Yuvaraj Sambandam ◽  
Jessica D. Hathaway‐Schrader ◽  
Azizul Haque ◽  
Chad M. Novince ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document